Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Other

The Ohio State University

Mds R&d (china) Co., Ltd.

Shankaran Kothandaraman

Sander G Mills

Lihu Yang

Changyou Zhou

Gregori J Morriello

Christopher Richard Moyes

Deodialsingh Guiadeen

Richard Jiao

Alexander Pasternak

Gabor Butora

Liping Wang

Stephen D Goble

Paul E Finke

Charles G Caldwell

Dooseop Kim

Bryan Oates

Cheng Tang

Malcolm MacCoss

Michael F Tweedle

Malcolm Maccoss

Ping Liu

Christopher Joseph Sinz

Jiaqiang Cai

Alejandro Crespo

Byron Dubois

Xiaoxing Du

Weiguo Quan

Rongqiang Liu

Li Gong

Chadwick Lewis Wright

Byron Gabriel Dubois

Disclosed are compositions and methods relating to novel tumor targeting peptides.

Peptide-based cancer imaging agents

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

Inhibitors of HIF prolyl hydroxylase

The present invention is directed to compounds of the formula I: (wherein R, R, R, R, R, R, R, R, R, R, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2. The present invention is also directed to intermediates useful in the preparation of formula I compounds.

Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to methods for treating, preventing, ameliorating, controlling or reducing the risk of an inflammatory or immunoregulatory disorder or disease, which method comprises the administration to a patient of an effective amount of the compound of formula I: (wherein R, R, R, R, R, R, R, R, R, R, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2 

Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity

Cyclic amine modulators of chemokine receptor activity

The present invention is directed to cyclic amines of the formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.

Growing community of inventors

Kendall Park, NJ, United States of America

Shankaran Kothandaraman